Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duelmen – page 37

1 729 clinical trials in Duelmen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duelmen at a glance
1 729
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 729 trials in Duelmen

Open in trial search

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Study on the Effect of Durvalumab and Tremelimumab with Radioactive Glass Spheres in Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Study on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.

Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Insel Gruppe AG

Study on the Effectiveness of E. coli DSM 17252 for Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:SymbioPharm GmbH

Colorectal cancer+1

Recruiting

Study on Preoperative Immunotherapy with Atezolizumab and Tiragolumab for Patients with Colorectal Liver Metastases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Universitaetsklinikum Essen AöR

Study on the Safety and Effectiveness of Tafasitamab for Children with Relapsed or Refractory Acute B Lineage Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tafasitamab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duelmen

What the registry says about research in the country

01 Immune System Diseases

In Dülmen, several recruiting studies focus on immune system diseases, especially psoriasis and chronic spontaneous urticaria. The research is aimed at finding better ways to control symptoms, assess treatment benefit, and support longer-term disease management.

  • Moderate to severe plaque psoriasis
  • Mild to moderate psoriasis
  • Chronic spontaneous urticaria
  • Evaluating treatment effectiveness and safety

These trials include studies of new therapies and comparisons with established options to improve care for people living with persistent inflammatory skin conditions.

02 Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases is a major part of the local clinical trial landscape, with studies covering atopic dermatitis, acne, and different forms of psoriasis. The overall goal is to test new topical and oral treatments that may offer better symptom relief and disease control.

  • Mild to moderate atopic dermatitis
  • Papulopustular acne
  • Chronic stable plaque psoriasis
  • Comparing new treatments with approved therapies or vehicle

These studies help researchers understand how well candidate treatments reduce skin inflammation, improve visible lesions, and support longer-lasting control of chronic skin disease.

03 Parasitic Diseases

Clinical research also includes parasitic diseases, with scabies being a key focus. The studies are designed to evaluate how well standard therapies work in clearing infection and restoring skin health.

  • Scabies
  • Assessing clinical response after treatment
  • Evaluating symptom resolution and treatment success

This area reflects practical, patient-centered research aimed at confirming effective care for a common contagious skin condition.

04 Topical Treatment Development

A number of trials in the city are centered on topical medicines for inflammatory skin disorders, including gels and ointments for acne, atopic dermatitis, and psoriasis. The focus is on comparing candidate products with approved treatments and non-active controls.

  • Testing new gels and ointments
  • Comparing against reference treatments
  • Improving local symptom control

These studies aim to refine everyday treatment options that may be easier to use and more effective for patients with chronic skin conditions.

05 Long-Term Disease Control

Some research is directed at long-term disease control, looking at how well treatments maintain benefit over time in chronic conditions such as psoriasis and urticaria. This helps determine whether a therapy can keep symptoms from returning or worsening.

  • Tracking time to disease worsening
  • Monitoring treatment durability
  • Supporting chronic disease management

Such studies are especially valuable for people who need sustained relief rather than short-term improvement alone.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.